Cargando…

Genome-wide transcriptomics identifies an early preclinical signature of prion infection

The clinical course of prion diseases is accurately predictable despite long latency periods, suggesting that prion pathogenesis is driven by precisely timed molecular events. We constructed a searchable genome-wide atlas of mRNA abundance and splicing alterations during the course of disease in pri...

Descripción completa

Detalles Bibliográficos
Autores principales: Sorce, Silvia, Nuvolone, Mario, Russo, Giancarlo, Chincisan, Andra, Heinzer, Daniel, Avar, Merve, Pfammatter, Manuela, Schwarz, Petra, Delic, Mirzet, Müller, Micha, Hornemann, Simone, Sanoudou, Despina, Scheckel, Claudia, Aguzzi, Adriano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7360066/
https://www.ncbi.nlm.nih.gov/pubmed/32598380
http://dx.doi.org/10.1371/journal.ppat.1008653
Descripción
Sumario:The clinical course of prion diseases is accurately predictable despite long latency periods, suggesting that prion pathogenesis is driven by precisely timed molecular events. We constructed a searchable genome-wide atlas of mRNA abundance and splicing alterations during the course of disease in prion-inoculated mice. Prion infection induced PrP-dependent transient changes in mRNA abundance and processing already at eight weeks post inoculation, well ahead of any neuropathological and clinical signs. In contrast, microglia-enriched genes displayed an increase simultaneous with the appearance of clinical signs, whereas neuronal-enriched transcripts remained unchanged until the very terminal stage of disease. This suggests that glial pathophysiology, rather than neuronal demise, could be the final driver of disease. The administration of young plasma attenuated the occurrence of early mRNA abundance alterations and delayed signs in the terminal phase of the disease. The early onset of prion-induced molecular changes might thus point to novel biomarkers and potential interventional targets.